Invesco Ltd. Purchases 63,068 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Invesco Ltd. lifted its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 54.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 178,619 shares of the company’s stock after buying an additional 63,068 shares during the period. Invesco Ltd.’s holdings in Recursion Pharmaceuticals were worth $1,207,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Envestnet Asset Management Inc. lifted its stake in Recursion Pharmaceuticals by 5.3% in the 4th quarter. Envestnet Asset Management Inc. now owns 231,756 shares of the company’s stock valued at $1,567,000 after acquiring an additional 11,646 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in Recursion Pharmaceuticals by 298.5% during the fourth quarter. Wells Fargo & Company MN now owns 458,321 shares of the company’s stock worth $3,098,000 after purchasing an additional 343,304 shares during the last quarter. Headlands Technologies LLC grew its position in Recursion Pharmaceuticals by 196.7% in the fourth quarter. Headlands Technologies LLC now owns 89,314 shares of the company’s stock valued at $604,000 after purchasing an additional 59,211 shares in the last quarter. Geode Capital Management LLC increased its stake in Recursion Pharmaceuticals by 12.1% in the 4th quarter. Geode Capital Management LLC now owns 6,087,149 shares of the company’s stock valued at $41,160,000 after buying an additional 655,238 shares during the last quarter. Finally, Franklin Resources Inc. lifted its position in Recursion Pharmaceuticals by 299.6% during the 4th quarter. Franklin Resources Inc. now owns 75,779 shares of the company’s stock worth $512,000 after buying an additional 56,816 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on RXRX shares. Cowen reaffirmed a “hold” rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. KeyCorp dropped their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Leerink Partners decreased their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a research note on Friday, February 28th. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 8th. Finally, Morgan Stanley decreased their price objective on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an “equal weight” rating for the company in a research report on Thursday, April 10th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $8.20.

Recursion Pharmaceuticals Stock Down 1.6 %

RXRX stock opened at $5.50 on Friday. Recursion Pharmaceuticals, Inc. has a 1-year low of $3.79 and a 1-year high of $12.36. The business’s 50 day simple moving average is $5.87 and its 200 day simple moving average is $6.75. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $2.21 billion, a PE ratio of -3.59 and a beta of 1.00.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). The company had revenue of $4.60 million for the quarter, compared to the consensus estimate of $19.04 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company’s revenue for the quarter was down 57.8% compared to the same quarter last year. During the same period last year, the firm earned ($0.42) earnings per share. As a group, research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.